SCHEDULE 13G: Pacer Funds and Affiliates Report 5.4% Passive Stake in Collegium Pharmaceutical

Pacer US Small Cap Cash Cows ETF, Pacer US Small Cap Cash Cows Growth Leaders ETF, Pacer Advisors, Inc., and Joe M. Thomson collectively reported a 5.4% beneficial ownership stake in Collegium Pharmaceutical, Inc. as of December 31, 2024, held for passive investment purposes.

Summary

• Pacer US Small Cap Cash Cows ETF, Pacer US Small Cap Cash Cows Growth Leaders ETF, Pacer Advisors, Inc., and Joe M. Thomson (collectively, the Reporting Persons) have filed a Schedule 13G indicating beneficial ownership of Collegium Pharmaceutical, Inc. common stock.
• As of December 31, 2024, the Reporting Persons collectively beneficially owned 2,142,491 shares of Collegium Pharmaceutical, Inc. common stock.
• This aggregate ownership represents 5.4% of the total 39,646,749 shares of common stock outstanding as of December 31, 2024.
• The shares are held for passive investment purposes in the ordinary course of business and not with the intent to change or influence control of the issuer.
• Pacer Advisors, Inc. serves as the investment adviser to the Pacer Funds, maintaining discretionary investment and voting authority over the shares held by the Funds.
• Joe M. Thomson is the majority stockholder of Pacer Advisors, Inc. and is deemed a beneficial owner, though both Pacer Advisors, Inc. and Mr. Thomson disclaim beneficial ownership of the shares held by the Funds.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of a passive beneficial ownership stake by an institutional investor, indicating continued investment interest in Collegium Pharmaceutical, Inc. without any stated intent to influence control. This is generally a neutral to slightly positive signal as it shows a significant investor holding shares.

Positives

• A significant institutional investor, Pacer Funds, holds a 5.4% stake, indicating their investment interest in Collegium Pharmaceutical, Inc.
• The investment is stated to be for passive purposes, not intended to influence or change control of the company, which suggests stability from this shareholder.

Negatives

• The document does not contain any negative information regarding Collegium Pharmaceutical, Inc.'s operations or financial performance.

Risks

• The Schedule 13G filing does not detail specific risks related to Collegium Pharmaceutical, Inc.'s business or operations.

Future Outlook

The document, a Schedule 13G, does not provide any forward-looking statements or guidance regarding Collegium Pharmaceutical, Inc.'s future outlook.

Management Comments

• Joe M. Thomson, Chairman and President of Pacer Funds Trust and President of Pacer Advisors, Inc., certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Industry Context

This Schedule 13G filing primarily concerns a change in beneficial ownership by an institutional investor and does not provide specific analysis of Collegium Pharmaceutical, Inc.'s position within the broader pharmaceutical industry or its competitive landscape.

Comparison to Industry Standards

• The document does not provide information for comparison to industry standards, specific comparable companies, projects, or results.

Stakeholder Impact

• Shareholders: The filing indicates a significant, passive institutional investor holding a 5.4% stake, which could be viewed as a vote of confidence in the company's long-term prospects without immediate implications for corporate control.
• Management: The passive nature of the investment suggests no immediate pressure or influence on management's strategic decisions from this particular shareholder group.

Next Steps

• The Reporting Persons will file amendments to this Schedule 13G if their beneficial ownership percentage changes by more than 1% or if their investment intent changes from passive.

Key Dates

Keywords

Collegium Pharmaceutical, Pacer US Small Cap Cash Cows ETF, Pacer US Small Cap Cash Cows Growth Leaders ETF, Pacer Advisors, Joe M. Thomson, Schedule 13G, beneficial ownership, common stock, SEC filing, institutional investment, passive investment, pharmaceuticals